ClinicalTrials.gg
CompletedNCT02943460Updated Jun 7, 2021Results posted

Study to Evaluate the Safety, Tolerability, and Efficacy of Cilofexor in Adults With Primary Sclerosing Cholangitis Without Cirrhosis

A Phase 2 interventional study of Cilofexor and Placebo to match cilofexor in Primary Sclerosing Cholangitis, sponsored by Gilead Sciences. Completed at 23 sites in 4 countries. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2021-06-07.

Sponsored by Gilead Sciences · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
52
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 75 studies in Cholangitis, Sclerosing with a site in United States — 19 open to participants now, 22 under way, 2 of them phase 3. Cholangitis, Sclerosing · United States.

Enrollment
23rd of 57
52 · median 27
Started
2016
with 6 others
Phase 2
26 of 75
6 open now
Registered
32nd of 75
by date
Lead sponsor
7 of 75
Gilead Sciences

Among the 75 studies in Cholangitis, Sclerosing with a site in United States, this one is the 23rd largest by enrollment of the 57 interventional ones that give a count, is one of 7 that started in 2016, is one of 26 in phase 2, and was the 32nd registered.

Cholangitis, Sclerosing

150 studies on the registry are indexed under Cholangitis, Sclerosing; 40 are open to participants now.

Browse Cholangitis, Sclerosing studies →

Open to participants now

19 of the 75 studies in Cholangitis, Sclerosing with a site in United States are open now. Recruiting first, the newest first:

14 more — sign in →

All 19 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 30 Cholangitis, Sclerosing studies recruiting now, 12 (40%) set no upper age limit and 13 (43%) stop at 75 or younger; 9 take children under 18; 9 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 75 studies in Cholangitis, Sclerosing with a site in United States, or all of them as a file.
02

Study summary

The primary objective of this study is to evaluate the safety and tolerability of cilofexor in adults with primary sclerosing cholangitis (PSC).

03

Conditions studied

  • Primary Sclerosing Cholangitis
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Diagnosis of PSC based on cholangiogram (magnetic resonance cholangiopancreatography (MRCP), endoscopic retrograde cholangiopancreatography (ERCP), or percutaneous transhepatic cholangiogram (PTC)) within the previous 12 months
  • Serum alkaline phosphatase (ALP) > 1.67 x (ULN)
  • For individuals on ursodeoxycholic acid (UDCA), the dose of UDCA must have been stable for at least 12 months prior to screening through the end of treatment. For individuals not on UDCA, no UDCA use for at least 12 months before screening through the end of treatment
  • For individuals being administered biologic treatments (eg, antitumor necrosis factor (TNF) or anti-integrin monoclonal antibodies), or systemic , the dose must have been stable at least 3 months prior to screening and anticipated to remain stable throughout the trial
  • Screening FibroSURE/FibroTest® \<0.75 unless a historical liver within 12 months of screening does not reveal cirrhosis. In adults with Gilbert's syndrome or hemolysis, FibroSURE/FibroTest® will be calculated using direct instead of total bilirubin.

Key Exclusion Criteria:

  • (ALT) > 10 x ULN
  • Total bilirubin > 2 x ULN
  • (INR) > 1.2 unless on anticoagulant therapy
  • Small-duct PSC (histologic evidence of PSC with normal bile ducts on cholangiography)
  • Other causes of liver disease including secondary sclerosing cholangitis and viral, metabolic, alcoholic, and other conditions. Individuals with hepatic steatosis may be included if there is no evidence of nonalcoholic steatohepatitis (NASH) in the opinion of the investigator or on liver biopsy;
  • Ascending cholangitis within 60 days of screening
  • Presence of a percutaneous drain or bile duct stent
  • Use of fibrates or obeticholic acid within 3 months prior to screening through the end of treatment
  • Cirrhosis of the liver as defined by any of the following:

    • Historical liver biopsy demonstrating cirrhosis (eg, Ludwig stage 4 or Ishak stage ≥ 5)
    • Prior history of decompensated liver disease, including ascites, hepatic encephalopathy or variceal bleeding
    • Liver stiffness > 14.4 kilopascal (kPa) by FibroScan
  • Current, active inflammatory bowel disease (IBD) defined as a partial Mayo score of > 1 and/or a score on the Rectal Bleeding domain > 0.

Note: Other protocol defined Inclusion/Exclusion criteria may apply.

Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
52 participants (actual)

Study arms

  • Experimental
    Cilofexor 100 mg (Blinded Study Phase)

    Cilofexor 100 mg + placebo to match cilofexor 30 mg for up to 12.6 weeks

    Drug: Cilofexor · Drug: Placebo to match cilofexor

  • Experimental
    Cilofexor 30 mg (Blinded Study Phase)

    Cilofexor 30 mg + placebo to match cilofexor 100 mg for up to 12.7 weeks

    Drug: Cilofexor · Drug: Placebo to match cilofexor

  • Placebo comparator
    Placebo (Blinded Study Phase)

    Placebo to match cilofexor 30 mg + placebo to match cilofexor 100 mg for up to 12.3 weeks

    Drug: Placebo to match cilofexor

  • Experimental
    Cilofexor (Open Label Extension Phase)

    Following the Blinded Study Phase, eligible participants received cilofexor for an additional up to 97.4 weeks.

    Drug: Cilofexor

Interventions

  • Tablet(s) administered orally once daily with food

    Also known as: GS-9674

  • DrugPlacebo to match cilofexor

    Tablet(s) administered orally once daily with food

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Experiencing Treatment-Emergent Adverse Events During the Blinded Phase

    Treatment-emergent adverse events occurring during the Blinded Phase were defined as 1 or both of the following: 1) Any adverse events (AEs) with an onset date on or after the study drug start date and no later than 30 days after permanent discontinuation of study drug in the Blinded Phase (and before the first dosing date in the Open Label Extension (OLE) Phase), or 2) Any AEs leading to premature discontinuation of study drug in the Blinded Phase.

    Time frame: First dose date up to last dose date plus 30 days (Up to 17 weeks)

  2. Percentage of Participants Experiencing Treatment-Emergent Serious Adverse Events During the Blinded Phase

    A serious adverse event was defined as an event that, at any dose, resulted in any of the following: death, life-threatening, in-patient hospitalization or prolongation of existing hospitalization, persistent or significant disability/incapacity, a congenital anomaly/birth defect, or a medically important event or reaction.

    Time frame: First dose date up to last dose date plus 30 days (Up to 17 weeks)

  3. Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities During the Blinded Phase

    Treatment-emergent laboratory abnormalities occurring during the Blinded Phase were defined as values that increase at least 1 toxicity grade from baseline at any postbaseline time point, up to and including the date of last dose of study drug in the Blinded Phase plus 30 days (and prior to or on the first dose date of the OLE phase). The Common Terminology Criteria for Adverse Events (CTCAE) Version 4.03 was used for assigning toxicity grades (0 to 4, with higher grades indicating more severity).

    Time frame: First dose date up to last dose date plus 30 days (Up to 17 weeks)

07

Results

Posted Mar 12, 2019

Participant flow

Participants were enrolled at study sites in North America and Europe. The first participant was screened on 29 November 2016. The last study visit occurred on 18 May 2020.

Blinded Study Phase
Participant flow — Blinded Study Phase
MilestoneCilofexor 100 mgCilofexor 30 mgPlacebo
Started222010
Completed191910
Not completed310
Withdrew: Adverse event300
Withdrew: Withdrew consent010
Open Label Extension (OLE) Phase
Participant flow — Open Label Extension (OLE) Phase
MilestoneCilofexor 100 mgCilofexor 30 mgPlacebo
Started191810
Completed14118
Not completed572
Withdrew: Adverse event252
Withdrew: Withdrew consent210
Withdrew: Investigator's discretion110

Outcome measures

PrimaryPercentage of Participants Experiencing Treatment-Emergent Adverse Events During the Blinded Phase

Treatment-emergent adverse events occurring during the Blinded Phase were defined as 1 or both of the following: 1) Any adverse events (AEs) with an onset date on or after the study drug start date and no later than 30 days after permanent discontinuation of study drug in the Blinded Phase (and before the first dosing date in the Open Label Extension (OLE) Phase), or 2) Any AEs leading to premature discontinuation of study drug in the Blinded Phase.

Time frame:
First dose date up to last dose date plus 30 days (Up to 17 weeks)
Reported as:
Number · percentage of participants
Percentage of Participants Experiencing Treatment-Emergent Adverse Events During the Blinded Phase
percentage of participantsCilofexor 100 mgCilofexor 30 mgPlacebo
Percentage of Participants Experiencing Treatment-Emergent Adverse Events During the Blinded Phase81.870.0100.0
PrimaryPercentage of Participants Experiencing Treatment-Emergent Serious Adverse Events During the Blinded Phase

A serious adverse event was defined as an event that, at any dose, resulted in any of the following: death, life-threatening, in-patient hospitalization or prolongation of existing hospitalization, persistent or significant disability/incapacity, a congenital anomaly/birth defect, or a medically important event or reaction.

Time frame:
First dose date up to last dose date plus 30 days (Up to 17 weeks)
Reported as:
Number · percentage of participants
Percentage of Participants Experiencing Treatment-Emergent Serious Adverse Events During the Blinded Phase
percentage of participantsCilofexor 100 mgCilofexor 30 mgPlacebo
Percentage of Participants Experiencing Treatment-Emergent Serious Adverse Events During the Blinded Phase13.600
PrimaryPercentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities During the Blinded Phase

Treatment-emergent laboratory abnormalities occurring during the Blinded Phase were defined as values that increase at least 1 toxicity grade from baseline at any postbaseline time point, up to and including the date of last dose of study drug in the Blinded Phase plus 30 days (and prior to or on the first dose date of the OLE phase). The Common Terminology Criteria for Adverse Events (CTCAE) Version 4.03 was used for assigning toxicity grades (0 to 4, with higher grades indicating more severity).

Time frame:
First dose date up to last dose date plus 30 days (Up to 17 weeks)
Reported as:
Number · percentage of participants
Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities During the Blinded Phase
percentage of participantsCilofexor 100 mgCilofexor 30 mgPlacebo
Any Grade 1 or Higher90.985.0100.0
Grade 122.725.010.0
Grade 236.435.060.0
Grade 327.320.030.0
Grade 44.55.00

Adverse events

Collected over Blinded Phase: First dose date up to last dose date plus 30 days (Up to 17 weeks); OLE Phase: First dose date up to last dose date plus 30 days (Up to 102 weeks). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Cilofexor 100 mg (Blinded Phase)0/22 (0%)3/22 (13.6%)18/22 (81.8%)
Cilofexor 30 mg (Blinded Phase)0/20 (0%)0/20 (0%)14/20 (70%)
Placebo (Blinded Phase)0/10 (0%)0/10 (0%)10/10 (100%)
Cilofexor 100 mg (Open Label Extension Phase)0/47 (0%)10/47 (21.3%)41/47 (87.2%)
Most frequent serious events
Showing 10 of 17
Most frequent serious events
EventCilofexor 100 mg (Blinded Phase)Cilofexor 30 mg (Blinded Phase)Placebo (Blinded Phase)Cilofexor 100 mg (Open Label Extension Phase)
DiarrhoeaGastrointestinal disorders1/220/200/100/47
Rib fractureInjury, poisoning and procedural complications1/220/200/100/47
DehydrationMetabolism and nutrition disorders1/220/200/100/47
Acute kidney injuryRenal and urinary disorders1/220/200/100/47
Bile duct obstructionHepatobiliary disorders0/220/200/102/47
Abdominal painGastrointestinal disorders0/220/200/101/47
Abdominal pain lowerGastrointestinal disorders0/220/200/101/47
Abdominal pain upperGastrointestinal disorders0/220/200/101/47
Chest painGeneral disorders0/220/200/101/47
Cholangitis sclerosingHepatobiliary disorders0/220/200/101/47
Most frequent other events
Showing 10 of 63
Most frequent other events
EventCilofexor 100 mg (Blinded Phase)Cilofexor 30 mg (Blinded Phase)Placebo (Blinded Phase)Cilofexor 100 mg (Open Label Extension Phase)
PruritusSkin and subcutaneous tissue disorders8/225/206/1020/47
NauseaGastrointestinal disorders0/221/203/105/47
NasopharyngitisInfections and infestations5/225/202/1014/47
FatigueGeneral disorders3/223/202/106/47
Alanine aminotransferase increasedInvestigations0/220/202/101/47
Aspartate aminotransferase increasedInvestigations0/220/202/102/47
HeadacheNervous system disorders1/224/202/107/47
Abdominal pain upperGastrointestinal disorders4/222/201/105/47
ArthralgiaMusculoskeletal and connective tissue disorders0/221/201/105/47
Abdominal discomfortGastrointestinal disorders2/220/201/104/47

Baseline characteristics

Safety Analysis Set included all participants who received at least 1 dose of study drug.

Age, Continuous
Age, Continuous(years)Cilofexor 100 mgCilofexor 30 mgPlaceboTotal
Mean42 ± 8.646 ± 12.142 ± 10.943 ± 10.4
Sex: Female, Male
Sex: Female, Male(Participants)Cilofexor 100 mgCilofexor 30 mgPlaceboTotal
Female116522
Male1114530
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Cilofexor 100 mgCilofexor 30 mgPlaceboTotal
Race — Asian0213
Race — Black or African American4318
Race — White1715739
Race — Not Permitted0011
Race — Other1001
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Cilofexor 100 mgCilofexor 30 mgPlaceboTotal
Ethnicity — Hispanic or Latino0303
Ethnicity — Not Hispanic or Latino2117947
Ethnicity — Not Permitted1012
Region of Enrollment
Region of Enrollment(participants)Cilofexor 100 mgCilofexor 30 mgPlaceboTotal
Canada4228
Austria1001
United States1217736
United Kingdom5117
08

Study locations

23 sites
  • University of California, Davis Medical Center
    Sacramento, California 95817, United States
  • University of California San Francisco
    San Francisco, California 94143, United States
  • University of Colorado Denver
    Aurora, Colorado 80045, United States
  • Florida Digestive Health Specialists
    Lakewood Ranch, Florida 34211, United States
  • Schiff Center for Liver Diseases/University of Miami
    Miami, Florida 33136, United States
  • Indiana University Health University Hospital
    Indianapolis, Indiana 46202, United States
  • Minnesota Gastroenterology, P.A.
    Saint Paul, Minnesota 55117, United States
  • Duke University Medical Center
    Durham, North Carolina 27710, United States
  • The Liver Institute at Methodist Dallas Medical Center
    Dallas, Texas 75203, United States
  • Intermountain Medical Center - Transplant Services
    Murray, Utah 84107, United States
  • University of Virginia
    Charlottesville, Virginia 22908, United States
  • Bon Secours St. Mary's Hospital of Richmond, Inc.
    Richmond, Virginia 23226, United States
  • McGuire VA Medical Center
    Richmond, Virginia 23249, United States
  • Virginia Commonwealth University
    Richmond, Virginia 23298, United States
  • Swedish Organ Transplant and Liver Center
    Seattle, Washington 98104, United States
  • University of Washington
    Seattle, Washington 98104, United States
  • Universitätsklinik Klinik für Innere Medizin III
    Vienna, Austria
  • University of Calgary Liver Unit (Heritage Medical Research Clinic)
    Calgary, Alberta, Canada
  • Toronto Liver Centre
    Toronto, Ontario M6H 3M1, Canada
  • New Queen Elizabeth Hospital NHS Foundation Trust
    Birmingham, United Kingdom
  • Royal Free Hospital
    London, NW3 2QG, United Kingdom
  • King's College Hospital NHS Foundation Trust
    London, SE5 9RS, United Kingdom
  • Norfolk and Norwich University Hospital
    Norwich, NR4 7UY, United Kingdom
09

References and documents

Publications

  • Trauner M, Gulamhusein A, Hameed B, Caldwell S, Shiffman ML, Landis C, Eksteen B, Agarwal K, Muir A, Rushbrook S, Lu X, Xu J, Chuang JC, Billin AN, Li G, Chung C, Subramanian GM, Myers RP, Bowlus CL, Kowdley KV. The Nonsteroidal Farnesoid X Receptor Agonist Cilofexor (GS-9674) Improves Markers of Cholestasis and Liver Injury in Patients With Primary Sclerosing Cholangitis. Hepatology. 2019 Sep;70(3):788-801. doi: 10.1002/hep.30509. Epub 2019 Mar 10. PubMed 30661255 ↗
  • Trauner M, Bowlus CL, Gulamhusein A, Hameed B, Caldwell SH, Shiffman ML, Landis C, Muir AJ, Billin A, Xu J, Liu X, Lu X, Chung C, Myers RP, Kowdley KV. Safety and Sustained Efficacy of the Farnesoid X Receptor (FXR) Agonist Cilofexor Over a 96-Week Open-label Extension in Patients With PSC. Clin Gastroenterol Hepatol. 2023 Jun;21(6):1552-1560.e2. doi: 10.1016/j.cgh.2022.07.024. Epub 2022 Aug 4. PubMed 35934287 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2016 to primary completion in Feb 2018, 14 months.

Results were first posted in Mar 2019, 1 year after primary completion.

Of 23 phase 2 interventional studies under Cholangitis, Sclerosing, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 62. This study's 14 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 13, 2016
First posted
Oct 24, 2016
StartActual
Nov 29, 2016
Primary completionActual
Feb 28, 2018
CompletionActual
May 18, 2020
Results first posted
Mar 12, 2019
Last update
Jun 7, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 7, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02943460
Lead sponsor
Gilead Sciences
Responsible party
Sponsor
First posted
Oct 24, 2016
Start date
Nov 29, 2016
Primary completion
Feb 28, 2018
Completion
May 18, 2020
Results posted
Mar 12, 2019
Last update
Jun 7, 2021

Study contacts

Gilead Study Director
study director · Gilead Sciences

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cilofexor

Start the discussion